Results 151 to 160 of about 4,735,472 (312)

Metal-polyphenol nanomedicines for malignant tumor therapy. [PDF]

Front Chem
Li Z, Xin H, Chen J, Dai J, Zheng H, Shi S, Sun H, Lu W, Wang G, Liu Z, Zhao N.   +10 more
europepmc   +1 more source

Newsletter: A Report to the Physicians of Texas

, 1980
Quarterly newsletter from the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute discussing cancer care and research to inform physicians of recent developments in the ...
McBurney, Marcia K., M.D. Anderson Hospital and Tumor Institute   +1 more
core  

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Apoptotic Macrophage-Derived Vesicles Loaded with Oncolytic Virus for Tumor Therapy. [PDF]

Cancer Manag Res
Wang Z, Yan Z, Tan M, Deng J, Wang J.
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Bacteria mediated tumor therapy recent advances challenges and future perspectives. [PDF]

Discov Oncol
Mao W, Deng C.
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances. [PDF]

J Hematol Oncol
Wang Y, Zheng J, Li Z, Qu J, Ren Y, Cai Z, Li Y, Sun W, Jiang N, Cai C, Ruan K, Shi J, Zhang Z, Zhou J.   +13 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy. [PDF]

Discov Nano
Yang M, Huang Y, Qian W, Zhu J, Fei L, Jiao Z, Wang J, Wang Y, Zhu W, Chen S, Gong P, Wang Z, Lu Z, Liu R, Liu Z, Hong Q, Luo Q, Zhang L.   +17 more
europepmc   +1 more source